Amalgam Rx
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | $95.0k | Seed | |
* | $17.4m | Series A | |
* | N/A | Series B | |
Total Funding | CAD23.9m |
Recent News about Amalgam Rx
EditAmalgam Rx operates in the digital health sector, focusing on developing and deploying regulated software and algorithms that assist patients and healthcare providers in making informed decisions. The company serves a diverse clientele, including patients, healthcare providers, and clinical trial recruiters, across multiple continents. Amalgam Rx leverages its robust Quality Management System (QMS) and extensive experience with the FDA and other regulatory bodies to ensure compliance and efficacy of its Software as a Medical Device (SaMD) solutions. The business model revolves around creating and scaling digital health solutions that are cleared for use by regulatory authorities, thereby generating revenue through direct sales and partnerships with healthcare organizations and insurers. Amalgam Rx's mission is to empower better healthcare decisions through innovative digital therapeutics and support programs, ultimately transforming care delivery.
Keywords: digital health, regulated software, algorithms, patient support, provider support, clinical decision, SaMD, FDA compliance, global deployment, digital therapeutics.